WASHINGTON, March 1, 2012 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) released the following statement after the Kentucky Senate Judiciary Committee passed Senate Bill 3, legislation that would impose significant restrictions on safe and effective medicines containing pseudoephedrine (PSE), such as Advil Cold & Sinus, Allegra-D, Claritin-D, Mucinex D, and Sudafed. SB 3 would limit the amount of PSE consumers can buy to 15 grams a year and 3.6 grams a month. The measure now moves to the full Senate for consideration.
"Severe restrictions on cold and allergy medicines containing pseudoephedrine will prevent chronic allergy suffers and many Kentucky families from accessing affordable, quality healthcare they rely upon," said Scott Melville, president and chief executive officer of the CHPA. "For thousands of Kentuckians—especially those who suffer from seasonal allergy symptoms—there's absolutely no difference between a prescription mandate and Senate Bill 3, especially given the fact that the Commonwealth of Kentucky has one of the longest allergy seasons in the country. The significant gram limit called for in SB 3 would lead to involuntary time off work, lost wages and increased health expenses for many responsible Kentucky families and workers."
"Kentucky Senators made the right decision when they shut the door on SB 50 last week. We are hopeful that the Kentucky Senate will listen to their constituents and enact anti-meth policies that target criminals without burdening responsible workers and families with additional barriers to these legal medicines."
CHPA is the 131-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.
SOURCE Consumer Healthcare Products Association